The Short Answer: These Routes Are Not Equivalent
When asking whether NAD+ is better as an injection, capsule or IV, the first point is that a shared name does not make the products equivalent. An IV infusion places NAD+ into the circulation through a cannula. A subcutaneous or intramuscular injection places an injectable preparation into tissue, but direct human outcomes data for these routes are extremely sparse. Most studied capsules do not contain NAD+ itself. They contain precursors the body can use to make it, particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Niacin, or vitamin B3, also contributes to NAD+ synthesis pathways [1, 3, 4, 13].
NAD+ inside cells is essential to reactions involved in energy metabolism, DNA repair and cellular signalling. Its biological importance does not prove that increasing a blood marker treats fatigue, improves skin or slows ageing. Three separate questions matter: was the compound absorbed, did a biomarker change, and did the person experience a meaningful health benefit? Trials of NR and NMN often answer the first two questions, while functional and clinical outcomes remain limited and inconsistent [3, 4, 5, 6, 7, 8, 9].
There is therefore no simple scientific ranking that puts IV first, injection second and capsules third. Reaching the bloodstream faster is not automatically better for cells or for a health goal. A decision should start with a defined reason, the strength of evidence for the desired outcome, route-specific risks, product quality and whether a simpler cause of fatigue or poor concentration needs a different treatment [2, 3, 4].
IV NAD+: Direct Delivery Does Not Prove Greater Benefit
An IV infusion bypasses the stomach and intestine. That delivery feature matters when someone needs an established intravenous treatment or cannot absorb an oral therapy, but the phrase “complete absorption” can mislead. Entry into a vein does not reveal how much reaches each tissue, which molecular form arrives there, or whether it creates an outcome the person can feel [2, 3, 4].
A small exploratory human study tracked NAD+ and its metabolites during an extended IV infusion. NAD+ was rapidly removed from plasma during the early period, followed by changes in selected metabolites and urinary excretion. This shows that the body handles the infused compound rapidly, but it does not establish treatment of fatigue, poor concentration or skin ageing, and it did not randomly compare an infusion with capsules [2]. Two recent reviews of human evidence found that most clinical trials concerned oral precursors and did not provide a strong basis for treating IV NAD+ as superior for general health outcomes [3, 4].
An infusion also adds the burdens of a cannula, monitoring time and the possibility of pain, phlebitis, infection or a reaction during administration. A small retrospective study in a commercial setting recorded nausea, cramping, diarrhoea, increased heart rate and chest pressure during NAD+ administration, although its small non-randomized design cannot determine a risk rate for everyone [10]. “Direct delivery” therefore describes the route, not proven effectiveness or safety [2, 3, 10].
Subcutaneous or Intramuscular Injections: A Larger Evidence Gap
Subcutaneous and intramuscular injections are not miniature versions of an IV infusion. Absorption from tissue occurs at a different rate and depends on formulation, stability and injection site. More importantly, published human research does not provide a strong comparison of subcutaneous or intramuscular NAD+ with oral NR or NMN or IV NAD+ for energy, performance, skin or ageing outcomes [3, 4].
When a claim says an injection has “higher bioavailability,” ask what that means: entry into blood, an increase in one marker, or a health improvement? Bioavailability is not a synonym for clinical effectiveness. Without a direct trial measuring the same outcome, a capsule result cannot be assigned to an injection, and an IV disposition study cannot establish that an injection behaves identically [2, 3, 4].
Injection also adds local risks such as pain, redness, bruising, inflammation and infection. Any compounded injectable needs a reliable source, sterile preparation, clear labelling and storage that follows its instructions. The US Food and Drug Administration warned against using food-grade ingredients unsuitable for sterile NAD+ compounding after receiving reports of severe shaking, chills, vomiting and fatigue suspected to involve bacterial endotoxins [11]. This does not mean every NAD+ injection is contaminated, but it is a strong reason to reject an unknown product, self-injection or administration without appropriate supervision [11].
Capsules: NR, NMN and Niacin Are Not One Compound
Capsules have the largest body of human data among these options, but the ingredient matters more than the word NAD+ on the front. NR and NMN are different precursors entering NAD+ synthesis pathways. Niacin is a family name that includes nicotinic acid, nicotinamide and related forms. The gastrointestinal tract absorbs niacin and tissues convert it to NAD, but the forms have different adverse-effect profiles [13].
In short trials involving healthy adults or adults with overweight, NR increased blood NAD+ markers and was tolerated over the study period [5, 6]. A small randomized NMN trial increased blood NAD+ without obvious problems during follow-up [8]. Another trial in women with prediabetes found improved muscle insulin sensitivity without corresponding improvement in every whole-body outcome [7]. These are useful research signals, but they do not establish that every user will feel more energetic or receive a long-term benefit [4, 7, 8].
When NMN trials were pooled, a meta-analysis found no consistent improvement in fasting glucose, insulin, glycated haemoglobin, insulin resistance or blood lipids [9]. A capsule is more convenient than an IV procedure, but it is not risk-free. Supplements can interact with medicines and vary in quality, while pharmacological niacin can cause flushing, low blood pressure, altered glucose control and liver problems depending on the form and context [12, 13]. Do not stack multiple precursors or treat “natural” as a guarantee; review the complete ingredient list with a professional [11, 12, 13].
Trials Establish Biomarkers More Often Than Felt Benefits
The most consistent finding in NR and NMN research is that selected oral products can increase NAD+ or related metabolites in blood. Blood is not the whole body; tissues have distinct pathways, and a higher marker alone does not reveal what happened in muscle, brain or skin. A recent clinical review emphasized that evidence for age-related NAD+ decline in humans is limited and tissue-specific, while precursor trials have shown limited clinical efficacy despite compelling animal findings [4]. A newer systematic review reached the same broad conclusion: biological activity is clear, but wellness and anti-ageing outcomes are inconsistent and do not establish one superior route [3].
This distinction matters particularly for skin goals. Skin cells use NAD+ like other cells, and laboratory and animal research suggests possible mechanisms. Strong clinical evidence does not show that IV NAD+, injections or capsules improve wrinkles, elasticity or glow in healthy people, and no comparison establishes one route as better for skin [3, 4]. Sun protection, treatment of an existing skin disorder, adequate nutrition and sleep have different roles and should not be replaced by a biomarker claim.
The same reasoning applies to fatigue and concentration. If someone sleeps better or changes other habits while using a product, improvement does not prove NAD+ caused it. An appropriate randomized trial needs a comparison group, a defined outcome and sufficient follow-up. Most current trials are small and short, and some have funding or investigator links to the tested product. Sample size, design and conflicts of interest matter more than a marketing headline [3, 4, 5, 6, 7, 8, 9].
Quality, Sterility and Storage: What Should You Check?
The comparison does not end with absorption. For capsules, check the exact compound, amount and full ingredient list, and avoid a proprietary blend that hides quantities or claims to treat multiple diseases. In the United States, dietary supplements do not undergo the same premarket approval required for medicines, and the company initially carries responsibility for safety and truthful labelling. Being on sale is therefore not independent proof of effectiveness or quality [12]. Look for a traceable manufacturer, lot number, expiry date, intact seal and pharmacist or professional review when other medicines are involved.
The quality stakes are higher for injections and infusions because the product bypasses natural barriers. Ask who prepared it, whether the ingredient is suitable for sterile compounding and whether the container identifies the composition, lot, expiry and storage conditions. A cold chain is not a universal rule for every NAD+ product; follow the specific preparation's storage instructions and, when refrigeration is required, ask how the cold chain was documented from source to administration. Do not use a product with altered appearance, an expired date or an unclear source [11].
A professional should also review allergy history, medicines, pregnancy or breastfeeding and liver, kidney or heart disease before any injection or infusion, with monitoring during administration. Stop the procedure and seek immediate assessment for breathlessness, facial or tongue swelling, chest pain or pressure, severe dizziness, fainting, intense shaking or repeated vomiting [10, 11]. After an injection, increasing redness or pain, local warmth, discharge or fever needs prompt review for inflammation or infection [11].
Before Choosing: Seven Questions That Separate Evidence from Promotion
Before asking “which one should I take?”, write the goal in one clear sentence. Are you trying to address fatigue, change a laboratory marker or ask about skin? Each goal has different evidence. Ask which outcome was actually measured, how it was measured and whether the difference appeared only in a test or was something participants experienced. If a claim jumps from cells or mice to a promise for people, the evidence has not yet reached that outcome [3, 4].
Also ask exactly what the product contains. Is it NAD+, NR, NMN, niacin or a mixture? Who made it, and where are the lot number and expiry? For an injection or infusion, who prepared it and how were sterility and storage checked? If its instructions require refrigeration, how was the cold chain maintained? These are not extra details; they separate a traceable product from an unknown preparation [11, 12, 13].
Next ask about the real comparison. Did a trial compare both routes for the same goal, or is someone comparing rapid venous entry with a biomarker rise after a capsule? Ask when success will be assessed, what happens if it does not help and who will review symptoms. Disclose every medicine and supplement because duplicated niacin or multiple precursors can be combined without realizing it [12, 13].
Finally, ask whether a simpler cause has been missed. If sleep is inadequate, food intake is poor, or symptoms suggest anaemia or thyroid disease, the problem is not failure to choose the “best NAD+.” A sound decision does not have to end with a product; it may end with targeted testing, treatment of a deficiency or a clearer sleep, nutrition and follow-up plan [3, 4, 13].
Choose by the Reason: Sometimes the Basics Matter More Than NAD+
If persistent fatigue led you to search for NAD+, start with the cause before choosing a product form. Inadequate sleep or sleep apnoea, anaemia or iron deficiency, vitamin B12 deficiency, thyroid dysfunction, diabetes, contextually relevant vitamin D deficiency, medicine effects, anxiety or depression all require different assessments and treatments. Our guide to persistent fatigue and which tests to start with explains why investigations follow the history and examination rather than a fixed package [3, 4].
If fatigue accompanies cold intolerance, constipation, palpitations, weight change or other symptoms, read about the TSH test and thyroid results to see why a result is interpreted alongside symptoms and selected follow-up tests. If all fatigue has been attributed to vitamin D, review whether vitamin D deficiency causes fatigue because treating a documented deficiency differs from trying an unselected supplement or injection. Improving sleep, adequate food, appropriate activity and a confirmed deficiency has a measurable target; an NAD+ trial should not delay diagnosis of the cause [3, 4, 13].
An adult may discuss an option after medical assessment when they understand the evidence limits, have a defined goal and suitable monitoring, and no simpler alternative or condition needs treatment first. The medical team at La Rose can review symptoms, medicines, nutrition and indicated tests, assess whether the option fits and offer it only after assessment. To make a decision based on reasons and risks rather than promotion, you can book a consultation with the medical team at La Rose. The sound choice may be to treat a deficiency, correct fundamentals, select a simpler route, defer NAD+ or not use it [3, 4, 11, 12, 13].
